Lysis of Small Cell Carcinoma of the Lung (SCCL) Cells by Cytokine-Activated Monocytes and Natural Killer Cells in the Presence of Bispecific Immunoconjugates Containing a Gastrin-Releasing Peptide (GRP) Analog or a GRP Antagonist

Chen, J.; Zhou, Jiehua; Mokotoff, Michael; Fanger, M W; Ball, Edward D.

doi:10.1089/scd.1.1995.4.369

Cited by 13 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The general approach of coupling a small high-affinity ligand to antibodies against immune effector cells (Chen et al, 1995;Kranz et al, 1995) should be widely applicable to any type of cancer in which a high-affinity ligand against a tumor-associated molecule can be identified. The folate/antibody approach may work more effectively against tumors such as ovarian carcinomas that do not have the complication of the blood-brain barrier and that may be more accessible by T cells.…”

Section: Resultsmentioning

confidence: 99%

Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate

et al. 1998

View full text Add to dashboard Cite

High‐affinity receptors expressed on the surface of some tumors can be exploited by chemically conjugating the ligand for the receptor and an antibody against immune effector cells, thus redirecting their cytolytic potential against the tumor. Ovarian carcinomas and some brain tumors express the high‐affinity folate receptor (FR). In this report, a transgenic mouse model that generates endogenously arising choroid plexus tumors was used to show that folate/anti‐ T‐cell receptor antibody conjugates can direct infiltration of T cells into solid brain tumor masses. An engineered single‐chain Fv form of the anti‐T‐cell receptor antibody KJ16 was conjugated with folate, to produce a bispecific agent that was substantially smaller than most previously characterized bispecific antibodies. Folate conjugation to the antibody increased T‐cell infiltration into the tumors by 10‐ to 20‐fold, and significantly prolonged survival of the mice. Int. J. Cancer 76:761–766, 1998.© 1998 Wiley‐Liss, Inc.

show abstract

Section: Resultsmentioning

confidence: 99%

Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate

et al. 1998

View full text Add to dashboard Cite

show abstract

“…The former include coupling Bn analogues to iron oxide nanoparticles for enhancing sensitivity of magnetic resonance imaging [125,204], to various fluorescent molecules which can be used for in vivo imaging [41,173,187,222] or to nanorods containing a photoacoustic imaging moieties [108]. Potentially cytotoxic compounds include coupling Bn analogues to chemotherapeutic agents [camptothecin [88,227,232], doxorubicin [240,241,258], paclitaxel [303,304]]; marine toxins [230]; to diphtheria toxin [360]; to mitochondria-disruptive peptides [40]; to agents that activate polyclonal T lymphocytes [398]; coupled to other immunotherapeutic agents that lead to cell death [48,49]; to photosensitizers [73,73,236,282] and to siRNA or adenoviral delivery vectors[116,242,308,374,375,375]. In addition BnR agonists have been one of the main targeting agents coupled to various nanoparticle carriers to assess delivery [44,342] or for targeted delivery of various cytotoxic agents including chemotherapeutic agents [docataxel [157], doxorubicin [1,3]]; radiolabeled analogues [140]; or gold nanoparticles [45].…”

Section: Bnr Function In Disease and A Therapeutic Target (Table 3)mentioning

confidence: 99%

Insights into bombesin receptors and ligands: Highlighting recent advances

et al. 2015

View full text Add to dashboard Cite

This following article is written for Prof. Abba Kastin’s Festschrift, to add to the tribute to his important role in the advancement of the role of peptides in physiological, as well as pathophysiological processes. There have been many advances during the 35 years of his prominent role in the Peptide field, not only as editor of the journal Peptides, but also as a scientific investigator and editor of two volumes of the Handbook of Biological Active Peptides [146,147]. Similar to the advances with many different peptides, during this 35 year period, there have been much progress made in the understanding of the pharmacology, cell biology and the role of (Bombesin) Bn receptors and their ligands in various disease states, since the original isolation of bombesin from skin of the European frog Bombina bombina in 1970 [76]. This paper will briefly review some of these advances over the time period of Prof Kastin 35 years in the peptide field concentrating on the advances since 2007 when many of the results from earlier studies were summarized [128,129]. It is appropriate to do this because there have been 280 articles published in Peptides during this time on Bombesin-related peptides and it accounts for almost 5% of all publications. Furthermore, 22 Bn publications we have been involved in have been published in either Peptides [14,39,55,58,81,92,93,119,152,216,225,226,231,280,302,309,355,361,362] or in the Prof Kastin’s Handbook of Biological Active Peptides [137,138,331].

show abstract

“…In 1995 Chen et al published a paper [153,154] using Bn analog ([Lys 3 ]Bn, (Table 2) [Analog #10, Table 12] coupled to an antibody anti-FcγRI as an immunotherapeutic approach to the treatment of SCLC. This bispecific immunoconjugate should bind by one side to the GRP receptor expressed in SCLC cells and by the other to the FcγRI expressed in cells such as activated monocytes or neutrophils and produce lysis of the cancer cells.…”

Section: Review Of Human Radiolabeled Studies Of Bn Receptor-medimentioning

confidence: 99%

Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status

Sancho

Florio²,

Moody³

et al. 2011

CDD

134

209

View full text Add to dashboard Cite

The three mammalian bombesin (Bn) receptors (gastrin-releasing peptide [GRP] receptor, neuromedin B [NMB] receptor, BRS-3) are one of the classes of G protein-coupled receptors that are most frequently over-express/ectopically expressed by common, important malignancies. Because of the clinical success of somatostatin receptor-mediated imaging and cytotoxicity with neuroendocrine tumors, there is now increasing interest in pursuing a similar approach with Bn receptors. In the last few years then have been more than 200 studies in this area. In the present paper, the in vitro and in vivo results, as well as results of human studies from many of these studies are reviewed and the current state of Bn receptor-mediated imaging or cytotoxicity is discussed. Both Bn receptor-mediated imaging studies as well as Bn receptor-mediated tumoral cytotoxic studies using radioactive and non-radioactive Bn-based ligands are covered. Keywordsbombesin; gastrin-releasing peptide; neuromedin B; BRS-3; receptor-mediated imaging; tumor cytotoxicity; DOTA; DTPA; NOTA I. Bombesin (Bn) receptor family-General (Table 1,2)The mammalian Bn receptor family is receiving increased attention as a means of localizing tumors or other disease processes by receptor-mediated imaging or for receptor-mediated cytotoxicity of tumors [1][2][3][4][5]. This family got its unusual name, because the original members of this peptide family were isolated from various frog skins and were named after the frog they were isolated from, with the original amidated tetradecapeptide isolated from the European frog, Bombina bombina in 1970 [6][7][8] (Table 2). Subsequently, a large number of related peptides were isolated which were divided into three groups: the Bn-related peptides with a COOH terminal, Gly-His-Leu-Met-NH 2 , the ranatesin-litorin group with a COOH terminus of Gly-His-Phe-Met-NH 2 and the phyllolitorin group with a COOH terminus ending in Gly-Ser-Phe/Leu-Met-NH 2 (Table 2) [6][7][8]. Subsequently two mammalian equivalent peptides were isolated, gastrin-releasing peptide (GRP), a 27 amino Corresponding author: Dr R.T. Jensen, Building 10, Room 9C-103, National Institutes of Health, Bethesda, MD 20892, Phone-301-496-4201, Fax-301-402-0600, robertj@bdg10.niddk.nih.gov. * Both authors contributed equally to this work Conflict of Interest: None NIH Public Access Author ManuscriptCurr Drug Deliv. Author manuscript; available in PMC 2012 January 1. NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript acid peptide which shares the same seven COOH terminal amino acids with Bn (Table 2) [9] and the decapeptide, neuromedin B (NMB) (Tables 1,2) which shares 6 of the 7 COOH terminal amino acids with litorin (Table 2) [10]. Each of these peptides is widely distributed in both the central nervous system (CNS) and peripheral tissues, especially in the gastrointestinal (GI) tract [8]. Numerous studies demonstrate these two peptides are involved in a wide range of physiological and pathophysiological processes which include: in the CNS...

show abstract

Lysis of Small Cell Carcinoma of the Lung (SCCL) Cells by Cytokine-Activated Monocytes and Natural Killer Cells in the Presence of Bispecific Immunoconjugates Containing a Gastrin-Releasing Peptide (GRP) Analog or a GRP Antagonist

Cited by 13 publications

References 21 publications

Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate

Targeting T cells against brain tumors with a bispecific ligand-antibody conjugate

Insights into bombesin receptors and ligands: Highlighting recent advances

Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status

Contact Info

Product

Resources

About